心血管解决方案提供商T45 Labs完成2500万美元融资，以加速投资组合公司取得里程碑式的成就-动脉网

T45 LABS CLOSES OVERSUBSCRIBED $25M T45 FUND：TO ACCELERATE MILESTONE ACHIEVEMENTS FOR PORTFOLIO COMPANIES

CISION 等信源发布 2025-03-19 20:01



可切换为仅中文







Use of Funds to Advance Delivery of Breakthrough Cardiovascular Medical Devices

使用资金推进突破性心血管医疗设备的交付

To Large and Underserved Markets

面向庞大且服务不足的市场

SANTA CLARA, Calif.

加利福尼亚州圣克拉拉

，

March 19, 2025

2025年3月19日

/PRNewswire/ --

T45 Labs

T45实验室

, a specialized medical technology innovation company focused on accelerating the development of cardiovascular solutions for large and underserved markets, today announced the successful close of its

，一家专注于加速为大型且服务不足的市场开发心血管解决方案的专业医疗技术创新公司，今天宣布其 успешно завершила

$25 million

2500万美元

T45 Fund I. The oversubscribed fund demonstrates strong investor confidence in T45 Labs' mission to deliver breakthrough cardiovascular technologies that drive meaningful advancements in patient care.

T45基金I。该基金超额认购，表明投资者对T45实验室致力于提供突破性心血管技术、推动患者护理实质性进步的使命充满信心。

继续阅读

'We are thrilled to close T45 Fund I with the enthusiastic support of our investors as we continue to push the boundaries of cardiovascular innovation,' shared

“我们非常高兴在投资者的热情支持下完成T45基金I的募集，我们将继续推动心血管创新的边界，”分享道。

Marwan Berrada-Sounni

马尔万·贝拉达-苏尼

, Managing Director of T45 Labs. 'The Fund will advance and fuel development and clinical research programs for our growing portfolio of companies, allowing each to achieve critical milestones while located in our new state-of-the-art facility.'

T45实验室董事总经理表示：“该基金将推动我们不断增长的公司组合的发展和临床研究项目，使每个公司都能在我们全新的先进设施中实现关键的里程碑。”

The Fund will advance and fuel development and clinical research programs for our growing portfolio of companies.

该基金将推动并助力我们不断增长的公司组合的发展和临床研究计划。

Post this

发布这个

Located in Silicon Valley, CA, in a 25,000-square-foot facility, T45 Labs efficiently manages each step of device development for its portfolio companies and collaborates closely with leading clinicians to rapidly develop, refine, and commercialize innovative devices. The funds have already been committed and will continue to be directed toward advancing the milestones of T45 Labs' growing portfolio of cardiovascular medical device companies:.

位于加利福尼亚州硅谷的一座25,000平方英尺的设施中，T45 Labs高效管理其投资组合公司设备开发的每个步骤，并与领先的临床医生密切合作，快速开发、完善和商业化创新设备。这些资金已经到位，并将继续用于推动T45 Labs不断增长的心血管医疗设备公司组合的里程碑进展。

Advanced NanoTherapies

先进纳米疗法

: Introducing the next-generation of drug-coated balloons

：推出新一代药物涂层球囊

Vahaticor

瓦哈提科尔

: Transforming cardiac care for patients with coronary microvascular dysfunction

：为冠状动脉微血管功能障碍患者转变心脏护理

NuevoSono

新声

: Advancing intra-vascular imaging for unmatched image quality and clarity